Anebulo Pharmaceuticals, Inc. (OTCMKTS:ANEB – Get Free Report)’s stock price dropped 5.5% on Thursday. The stock traded as low as $0.26 and last traded at $0.26. Approximately 100 shares were traded during trading, a decline of 45% from the average daily volume of 183 shares. The stock had previously closed at $0.2750.
Anebulo Pharmaceuticals Trading Down 5.5%
The firm’s 50 day moving average price is $0.31 and its 200-day moving average price is $0.48. The company has a market cap of $10.60 million, a P/E ratio of -1.37 and a beta of -1.88.
Anebulo Pharmaceuticals Company Profile
Anebulo Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for acute cannabinoid intoxication and related medical emergencies. The company’s work is aimed at addressing the effects of cannabis and synthetic cannabinoids, including situations in which patients require urgent medical care.
Anebulo’s lead investigational product, ANEB-001, is an orally administered antagonist of the cannabinoid type 1 (CB1) receptor. The company is developing ANEB-001 to rapidly reverse the effects of cannabinoid intoxication, with potential applications in emergency and acute-care settings.
Featured Articles
- Five stocks we like better than Anebulo Pharmaceuticals
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
